Suppr超能文献

系统性硬化症患者护理的综合框架:对改善 SSc 中诊断和预防策略实践的全球响应。

A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc.

机构信息

New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, USA; Tulane University School of Medicine, New Orleans, USA; Louisiana State University School of Medicine, Section of Pulmonary Medicine, New Orleans, USA; University Medical Center - Comprehensive Pulmonary Hypertension Center and Interstitial Lung Disease Clinic Programs, New Orleans, USA.

Vanderbilt University Medical Center, Nashville, TN, USA.

出版信息

Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101707. doi: 10.1016/j.berh.2021.101707. Epub 2021 Sep 15.

Abstract

Systemic sclerosis (SSc), the most lethal of rheumatologic conditions, is the cause of death in >50% of SSc cases, led by pulmonary fibrosis followed by pulmonary hypertension and then scleroderma renal crisis (SRC). Multiple other preventable and treatable SSc-related vascular, cardiac, gastrointestinal, nutritional and musculoskeletal complications can lead to disability and death. Vascular injury with subsequent inflammation transforming to irreversible fibrosis and permanent damage characterizes SSc. Organ involvement is often present early in the disease course of SSc, but requires careful history-taking and vigilance in screening to detect. Inflammation is potentially reversible provided that treatment intensity quells inflammation and other immune mechanisms. In any SSc phenotype, opportunities for early treatment are prone to be under-utilized, especially in slowly progressive phenotypes that, in contrast to severe progressive ILD, indolently accrue irreversible organ damage resulting in later-stage life-limiting complications such as pulmonary hypertension, cardiac involvement, and malnutrition. A single SSc patient visit often requires much more physician and staff time, organization, vigilance, and direct management for multiple organ systems compared to other rheumatic or pulmonary diseases. Efficiency and efficacy of comprehensive SSc care enlists trending of symptoms and bio-data. Financial sustainability of SSc care benefits from understanding insurance reimbursement and health system allocation policies for complex patients. Sharing care between recognised SSc centers and local cardiology/pulmonary/rheumatology/gastroenterology colleagues may prevent complications and poor outcomes, while providing support to local specialists. As scleroderma specialists, we offer a practical framework with tools to facilitate an optimal, comprehensive and sustainable approach to SSc care. Improved health outcomes in SSc relies upon recogntion, management and, to the extent possible, prevention of SSc and treatment-related complications.

摘要

系统性硬化症(SSc)是最致命的风湿性疾病,导致>50%的 SSc 病例死亡,其死亡原因主要为肺纤维化,其次为肺动脉高压,然后是硬皮病肾危象(SRC)。多种其他可预防和可治疗的 SSc 相关血管、心脏、胃肠道、营养和肌肉骨骼并发症可导致残疾和死亡。血管损伤随后发生炎症,转化为不可逆转的纤维化和永久性损伤,是 SSc 的特征。器官受累通常在 SSc 的疾病早期就存在,但需要仔细询问病史和警惕筛查以发现。只要治疗强度能抑制炎症和其他免疫机制,炎症就具有潜在的可逆性。在任何 SSc 表型中,早期治疗的机会都容易被低估,尤其是在进展缓慢的表型中,与严重进展性ILD 相反,ILD 缓慢进展,不可逆转地累积器官损伤,导致后期生命限制并发症,如肺动脉高压、心脏受累和营养不良。与其他风湿性或肺部疾病相比,单个 SSc 患者就诊通常需要医生和工作人员花费更多的时间、组织、警惕性和直接管理多个器官系统。综合 SSc 护理的效率和效果需要对症状和生物数据进行趋势分析。了解复杂患者的保险报销和卫生系统分配政策有助于 SSc 护理的财务可持续性。在认可的 SSc 中心和当地心脏病学/肺病学/风湿病学/胃肠病学同事之间共享护理可以预防并发症和不良结局,同时为当地专家提供支持。作为硬皮病专家,我们提供了一个实用的框架和工具,以促进 SSc 护理的最佳、全面和可持续方法。改善 SSc 的健康结果依赖于对 SSc 和治疗相关并发症的识别、管理和在可能的情况下预防。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e3/8670736/c25398f33e12/nihms-1742238-f0001.jpg

相似文献

4
Evaluation and management approaches for scleroderma lung disease.硬皮病肺病的评估与管理方法
Ther Adv Respir Dis. 2017 Aug;11(8):327-340. doi: 10.1177/1753465817713680. Epub 2017 Jun 16.
5
[Systemic sclerosis].[系统性硬化症]
Rev Prat. 2017 Sep;67(7):775-783.
6
Pulmonary hypertension in systemic sclerosis: different phenotypes.系统性硬皮病中的肺动脉高压:不同表型。
Eur Respir Rev. 2017 Sep 27;26(145). doi: 10.1183/16000617.0056-2017. Print 2017 Sep 30.
9
Determinants of morbidity and mortality of systemic sclerosis in Canada.加拿大系统性硬化症发病率和死亡率的决定因素。
Semin Arthritis Rheum. 2010 Feb;39(4):269-77. doi: 10.1016/j.semarthrit.2008.06.002. Epub 2008 Aug 15.

引用本文的文献

8
Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis.copeptin作为系统性硬化症微循环改变的生物标志物。
Clin Cosmet Investig Dermatol. 2023 May 25;16:1351-1361. doi: 10.2147/CCID.S409490. eCollection 2023.

本文引用的文献

1
Geographic disparity in systemic sclerosis mortality in the United States: 1999-2017.1999 - 2017年美国系统性硬化症死亡率的地区差异
J Scleroderma Relat Disord. 2021 Jun;6(2):139-145. doi: 10.1177/2397198319869566. Epub 2019 Aug 26.
4
8
Racial Disparities in Systemic Sclerosis.系统性硬化症中的种族差异。
Rheum Dis Clin North Am. 2020 Nov;46(4):705-712. doi: 10.1016/j.rdc.2020.07.009. Epub 2020 Sep 8.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验